alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › mri

mri

843 studies tagged mri, dated 1983-08-01 to 2026-09-25. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Diagnostic accuracy of remote self-administered digital cognitive assessment by clinical diagnosis and Alzheimer's disease PET imaging biomarkers 2026-09-25
  2. Multi-scale 3D CNN with imbalance-aware training for structural MRI-based six-class Alzheimer disease staging 2026-09-22
  3. T1 mapping in Alzheimer’s disease: a quantitative MRI study with amyloid-PET correlation 2026-09-21

Studies

843 studies carry this tag.

Date range

1983 to 2026

Top journals

  • Neurology 83
  • Journal of nuclear medicine : official publication, Society of Nuclear Medicine 42
  • Brain : a journal of neurology 34
  • NeuroImage 31
  • Alzheimer s & Dementia 30

283 journals in all.

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Multi-class Alzheimer’s disease (AD) classification using Swin Transformer wavelet and Gray Wolf Optimization (GWO)

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Intelligence-Based Medicine 2026-02-26 Brain scans and imaging

    Alzheimer’s disease (AD) is a slow-growing neurological disorder that destroys human thought and consciousness.

  2. Alzheimer’s related dementia severity classification from magnetic resonance imaging using derivative-free optimization of convolutional neural network

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Scientific Reports 2026-02-21 Getting a diagnosis

    Magnetic resonance imaging based dementia severity assessment facilitates timely diagnosis of Alzheimer’s disease (AD) progression.

  3. Advancing Theranostics in Alzheimer Disease: FDA Approval of Amyloid- PET Drugs for Selection of Patients for Amyloid-ߖDirected Therapies and Other Labeling Updates

    ✓ Peer-reviewed alzhub usefulness score 31 out of 100. Journal of Nuclear Medicine 2026-02-19 Biomarkers

    Theranostics—the use of diagnostic and therapeutic drugs that target the same molecular marker of disease—extends beyond the paradigm of radiopharmaceutical drug pairs used in oncologic settings (e.g., somatostatin receptor subtype 2 and prostate-specific membrane antigen theranostics) to other

  4. Convolutional Neural Network Achieves 97.67 Percent Accuracy for Alzheimer MRI Classification

    ✓ Peer-reviewed alzhub usefulness score 32 out of 100. Academia Open 2026-02-17 Brain scans and imaging

    Using approximately 5,000 ADNI MRI images, the model achieved 97.67% accuracy, 97.73% precision, 97.67% recall, and 97.65% F1-score, with AUC values near 1.00.

  5. An Artificial Intelligence-Driven Multimorbidity Framework Reveals a Shared Metabolic and Immune Core Across Alzheimer’s Disease, Amyotrophic Lateral Sclerosis, and Frontotemporal Dementia

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Biomedicines 2026-02-16 Digital health tools

    Across AD, ALS, and FTD, a convergent multimorbidity architecture centered on a shared metabolic and immune core was identified, accompanied by prominent neurobehavioral processes and intermediate systems including gastrointestinal, endocrine, hematological, hepatic, and sensory pathways.

  6. Progression-Aware and Explainable CNN–Transformer Framework for Multiclass Alzheimer’s Disease Staging Using MRI

    ✓ Peer-reviewed alzhub usefulness score 35 out of 100. Diagnostics 2026-02-16 Brain scans and imaging

    The experimental findings on a multiclass MRI dataset of Alzheimer disease demonstrate consistent and high performance across cross-validation folds (mean F1-score (0.991 ± 0.003) and AUROC (0.9998 ± 0.0002)), without losing transparency and progress awareness.

  7. Centiloids in Amyloid PET: A Practical Guide to Quantitation Interpretation

    ✓ Peer-reviewed alzhub usefulness score 44 out of 100. Journal of Nuclear Medicine Technology 2026-02-10 Biomarkers

    The approval of disease-modifying antiamyloid therapies has expanded the clinical role of amyloid PET beyond diagnostic confirmation to include baseline characterization and longitudinal monitoring of treatment response.

  8. PET Imaging in Alzheimer Disease in the Era of Antiamyloid Therapy in the United States: Clinical Utility, Quantification, and Policy Landscape

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Journal of Nuclear Medicine Technology 2026-02-10 Biomarkers

    Amyloid PET enables improved detection of amyloid-β plaques within the brain.

  9. Quantitative Amyloid Brain Imaging: A Literature Review of the Centiloid Scale in Alzheimer Disease Evaluation

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. Journal of Nuclear Medicine Technology 2026-02-10 Biomarkers

    The Centiloid method demonstrates strong intertracer and interscanner harmonization when standardized to the 11C-Pittsburgh compound B reference, with high correlation (r2 > 0.9) across 18F-labeled tracers, including florbetapir, flutemetamol, and florbetaben.

  10. Sex Differences in Alzheimer Disease Imaging Biomarkers in a Diverse, Community-Based Cohort

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Carolina Digital Repository (University of North Carolina at Chapel Hill) 2026-02-06 Genetics

    Compared with men, women had greater amyloid burden (B = 0.05; 95% CI, 0.02-0.07; P < .001), Braak stages III and IV (B = 0.05; 95% CI, 0.02-0.08; P = .003) and Braak stages V and VI (B = 0.09; 95% CI, 0.06-0.12; P < .001) tau burden, and AD signature thickness (B = 0.04; 95% CI, 0.02-0.05; P < .001).

  11. Failure of 18F-florbetapir Amyloid PET Imaging after Injection With an Automated Injector Using an Air-vent Filter for FDG Injection

    ✓ Peer-reviewed alzhub usefulness score 29 out of 100. Clinical Nuclear Medicine 2026-02-03 Biomarkers

    A 77-year-old woman with mild cognitive impairment was referred to 18F-florbetapir positron emission tomography (PET) to assess the indication of a disease-modifying drug against Alzheimer disease.

  12. GABAergic activity and gamma oscillations in Alzheimer’s disease and mild cognitive impairment: Neuropathology and therapeutic neuromodulatory insights from animal and human studies

    ✓ Peer-reviewed alzhub usefulness score 49 out of 100. Brain Network Disorders 2026-01-30 Mild cognitive impairment

    Disruptions in GABAergic activity and alterations in gamma oscillations are key pathological features of AD associated with amyloid-beta (Aβ) plaques.

  13. Sex Differences in Alzheimer Disease Imaging Biomarkers in a Diverse, Community-Based Cohort

    ✓ Peer-reviewed alzhub usefulness score 55 out of 100. JAMA Network Open 2026-01-27 Genetics

    A total of 503 participants (mean [SD] age, 64.6 [2.8] years; 321 [63.8%] women; 305 [60.6%] Hispanic, 120 [23.9%] non-Hispanic Black, and 78 [15.5%] non-Hispanic White) with Aβ PET, MRI (n = 501), and tau PET (n = 355) data were studied.

  14. Copathologies of Limbic-Predominant Age-Related TDP-43 Encephalopathy and Alzheimer Disease: [ 18 F]FDG PET Statistical Mapping and Quantitative MRI Volumetry

    ✓ Peer-reviewed alzhub usefulness score 46 out of 100. Journal of Nuclear Medicine 2026-01-22 Biomarkers

    Of the 944 clinical cases, 13.0% were characterized as probable LATE (2.4% pure LATE and 10.6% LATE+AD) and 23.7% were characterized as probable AD without LATE.

  15. Use of explainable AI (xAI) in dementia detection and prognosis: a scoping review

    ✓ Peer-reviewed alzhub usefulness score 57 out of 100. BMC Medical Informatics and Decision Making 2026-01-16 Disparities

    Dementia poses a significant global health challenge for both clinicians and patients, impacting millions of individuals worldwide, yet its early diagnosis remains underexplored.

  16. Effective deep convolutional neural network with attention mechanism for Alzheimer disease classification

    ✓ Peer-reviewed alzhub usefulness score 37 out of 100. Frontiers in Radiology 2026-01-14 Brain scans and imaging

    The proposed Deep-CNN and attention model focuses the model capacity on diagnostically relevant regions.

  17. Synthesis of Amyloid Images Using a Generative Adversarial Network from 2-Dimensional 18 F-FDG Images and Evaluation for Clinical Use

    ✓ Peer-reviewed alzhub usefulness score 30 out of 100. Journal of Nuclear Medicine Technology 2026-01-13 Brain scans and imaging

    Synthetic images were visually consistent, producing plausible negative and positive patterns while preserving continuity in the sagittal plane.

  18. An Ensemble Learning Artificial Intelligence Model for Alzheimer's Disease Detection Using OCT

    ✓ Peer-reviewed alzhub usefulness score 54 out of 100. Ophthalmology Science 2026-01-10 Digital health tools

    For detecting AD-dementia, the ensemble model achieved the area under the receiver operating characteristic curve (AUROC) of 0.943 (95% confidence interval, 0.906-0.980), 0.786 (95% confidence interval, 0.673-0.899), and 0.795 (95% confidence interval, 0.716-0.874) in the internal validation, External-1, and External-2, respectively.

  19. EEG-based classification of alzheimer’s disease and frontotemporal dementia using functional connectivity

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Scientific Reports 2026-01-09 Lewy body dementia

    Overall, these findings highlight the potential of EEG connectivity features for dementia classification and emphasize the importance of careful feature engineering and low-complexity models in the case of small-sample datasets.

  20. Additive value of early-phase β-Amyloid-PET for the differential diagnosis of non-Alzheimer’s disease dementia

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. NeuroImage Clinical 2026-01-01 Biomarkers

    Neurodegeneration status was correctly identified in 78.8% (119/151) of amyloid-negative patients through visual rating, compared to 67.5% (102/151) using logistic regression.

  21. Longitudinal Structural MRI-Based Deep Learning And Radiomics Features For Predicting Alzheimer\\\\\\\'s Disease Progression

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Zenodo (CERN European Organization for Nuclear Research) 2026-01-01 Brain scans and imaging

    Alzheimer\\\'s disease (AD), the leading cause of dementia worldwide, affects more than 55 million individuals and gen-erates annual healthcare costs exceeding two trillion USD [14].

  22. Longitudinal Structural MRI-Based Deep Learning And Radiomics Features For Predicting Alzheimer\\\\\\\'s Disease Progression

    ✓ Peer-reviewed alzhub usefulness score 55 out of 100. Zenodo (CERN European Organization for Nuclear Research) 2026-01-01 Brain scans and imaging

    Alzheimer\\\'s disease (AD), the leading cause of dementia worldwide, affects more than 55 million individuals and gen-erates annual healthcare costs exceeding two trillion USD [14].

  23. Multimodal Deep Learning for Dynamic and Static Neuroimaging: Integrating MRI and fMRI for Alzheimer Disease Analysis

    ✓ Peer-reviewed alzhub usefulness score 32 out of 100. Journal of Machine Learning for Modeling and Computing 2026-01-01 Brain scans and imaging

    Magnetic Resonance Imaging (MRI) provides detailed structural information, while functional MRI (fMRI) captures temporal brain activity.

  24. Structural Brain Correlates With Appetite and Eating Disturbances Across the Alzheimer Disease Spectrum

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. Alzheimer Disease & Associated Disorders 2026-01-01 Brain scans and imaging

    Appetite disturbances were present in 9.4% of participants and were associated with greater neuropsychiatric burden and disease severity.

  25. The Diagnostic Role of FDG-PET in Dementias Presenting with Language and Behavioral Symptom

    ✓ Peer-reviewed alzhub usefulness score 28 out of 100. Turk psikiyatri dergisi = Turkish journal of psychiatry 2026-01-01 Tau biomarkers

    This study aimed to assess the diagnostic contribution of Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in neurodegenerative dementias presenting with language-predominant symptoms, with or without accompanying behavioral changes, and to evaluate the correspondence between PET-derived metabolic patterns and cerebrospinal fluid (CSF) biomarkers.

  26. Application of Convolutional Neural Network Based on ResNet18 for Alzheimer Disease Classification

    ✓ Peer-reviewed alzhub usefulness score 28 out of 100. International Journal of Artificial Intelligence Research 2025-12-30 Brain scans and imaging

    Alzheimer's disease is a form of progressive dementia that significantly impacts the quality of life of patients and their families.

  27. Klasifikasi Penyakit Alzheimer menggunakan CNN dengan pretrained VGG19 dan SMOTE berdasarkan Citra MRI Otak

    ✓ Peer-reviewed alzhub usefulness score 28 out of 100. Arcitech Journal of Computer Science and Artificial Intelligence 2025-12-30 Brain scans and imaging

    Early detection of Alzheimer's disease is crucial for effective treatment, and the use of brain MRI images has become a common method for diagnosis.

  28. Utility of the Amygdalar Atrophy Scale to Identify Patients With Limbic-Predominant Age-Related TDP-43 Encephalopathy in a Memory Clinic

    ✓ Peer-reviewed alzhub usefulness score 56 out of 100. Neurology 2025-12-22 Laboratory science

    The analytic sample included 469 participants (mean age 71.2 ± 8.5 years, 53% female).

  29. FDA approval of the Lumipulse G pTau217/β-amyloid 1-42 plasma ratio test: a new era in accessible Alzheimer's diagnosis

    ✓ Peer-reviewed alzhub usefulness score 42 out of 100. Annals of Medicine and Surgery 2025-12-17 Getting a diagnosis

    This review article discusses the FDA's May 2025 clearance of Fujirebio's Lumipulse G blood test, the first FDA-cleared blood test for aiding Alzheimer's diagnosis (via the pTau217/beta-amyloid 1-42 ratio).

  30. Ophthalmic imaging and artificial intelligence in early diagnosis of Alzheimer disease

    ✓ Peer-reviewed alzhub usefulness score 27 out of 100. Neurology Bulletin 2025-12-16 Brain scans and imaging

    Alzheimer disease represents a major medical and social challenge owning to the complexity of its diagnosis, especially at the preclinical stage.

  31. Radionuclide Selection Influences Imaging Outcomes in Immuno-PET with a Brain-Penetrating Anti–Amyloid-β Antibody

    ✓ Peer-reviewed alzhub usefulness score 32 out of 100. Journal of Nuclear Medicine 2025-12-11 Treatments

    PET imaging demonstrated high cortical brain uptake of all 3 radiotracers in Tg-ArcSwe mice.

  32. Alzheimer disease predicting from clinical and MRI data using DeepALZNET dual pathway framework

    ✓ Peer-reviewed alzhub usefulness score 35 out of 100. Scientific Reports 2025-12-04 Brain scans and imaging

    Alzheimer's Disease (AD) is a significant neurological condition characterized by progressive cognitive deterioration, with prevalence rising exponentially with age.

  33. Longitudinal assessment of cognitive decline and resilience in high-level Alzheimer disease neuropathologic change

    ✓ Peer-reviewed alzhub usefulness score 56 out of 100. Alzheimer s Research & Therapy 2025-12-03 Genetics

    Individuals with rapid progression were more likely to have at least one APOE ε4 allele (OR: 2.08 [95% CI: 1.16–3.74], p < 0.01), higher Braak stage (2.19 [1.20–3.98], p < 0.01), higher Thal phase (2.45 [1.24–4.83], p < 0.01), more severe white matter rarefaction (1.68 [1.21–2.35], p < 0.01), and in the final 24 months of life, more frequent untreated/undertreated hyperlipidemia (1.74 [1.35–5.56], p < 0.01) and less frequent untreated/undertreated depression (0.40 [0.17–0.91], p < 0.05).

  34. Clinical and pathologic correlations of machine learning quantification of Aβ deposits across 3 brain regions of decedents with Alzheimer disease

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Journal of Neuropathology & Experimental Neurology 2025-12-02 Genetics

    Machine learning enables scalable quantification of neuropathology, offering deeper phenotyping of Alzheimer's disease (AD).

  35. Physical and Cognitive Activities and Trajectories of AD Neuroimaging Biomarkers

    ✓ Peer-reviewed alzhub usefulness score 50 out of 100. Neurology 2025-12-02 Disease mechanisms

    = 0.038) over time. Physical activity was associated with less synaptic dysfunction and cognitive activity with less synaptic dysfunction and lower amyloid burden over time, albeit effect sizes were small.

  36. AD-HOLDER: Alzheimer’s Disease Detection via Machine Learning based Histograms of Light GBM Classifier using MRI and PET Images

    ✓ Peer-reviewed alzhub usefulness score 31 out of 100. Measurement Science Review 2025-12-01 Brain scans and imaging

    Alzheimer’s disease (AD) is an irreversible brain condition that impairs memory and cognitive processes.

  37. Application of supervised and unsupervised machine learning approaches to identify somatic T‐cell receptor sequence variation in Alzheimer disease among Midwestern Amish

    ✓ Peer-reviewed alzhub usefulness score 37 out of 100. Alzheimer s & Dementia 2025-12-01 Genetics

    Participants did not differ significantly based on sex.

  38. Correlating antemortem amyloid PET burden, postmortem MRI volumes, with neuropathological measures: Insights from Down syndrome and Alzheimer's disease cohorts

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Alzheimer s & Dementia 2025-12-01 Down syndrome and Alzheimer's

    The ABC-DS cohort showed similar Aβ PET burden but had a lower prevalence of ApoE4 carriers, younger age at clinical diagnosis and autopsy, shorter PET-autopsy interval, smaller amygdala and hippocampal volumes, more advanced CERAD scores, and no atherosclerosis compared to ADRC cohort (Figure 1).

  39. Diagnostic Accuracy of FDG‐PET‐CT in Dementia: Assessing False Negatives in Clinical Practice

    ✓ Peer-reviewed alzhub usefulness score 49 out of 100. Alzheimer s & Dementia 2025-12-01 Getting a diagnosis

    The proportion of false negatives from FDG-PET ranged from 11-55%.

  40. Imaging‐neuropathology evaluation of Amyloid Related Imaging Abnormality sulcal effusion in a DIAN‐TU‐001 participant treated with gantenerumab

    ✓ Peer-reviewed alzhub usefulness score 44 out of 100. Alzheimer s & Dementia 2025-12-01 Treatments

    Overall PiB-PET uptake increased during the first two years (before ARIA-E) and decreased during the last two years (including ARIA-E episodes) (0.03±0.05 vs. -0.04±0.04 SUVR/year, p-value=0.01, Figure 2).

  41. Imaging‐neuropathology evaluation of Amyloid Related Imaging Abnormality sulcal effusion in a DIAN‐TU‐001 participant treated with gantenerumab

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Alzheimer s & Dementia 2025-12-01 Treatments

    Overall PiB-PET uptake increased during the first two years (before ARIA-E) and decreased during the last two years (including ARIA-E episodes) (0.03±0.05 vs. -0.04±0.04 SUVR/year, p-value=0.01, Figure 2).

  42. Metabolomic Signatures and Machine Learning Models for Distinguishing Alzheimer's Disease and Dementia with Lewy Bodies

    ✓ Peer-reviewed alzhub usefulness score 37 out of 100. Alzheimer s & Dementia 2025-12-01 Digital health tools

    AD patients exhibited a significantly higher prevalence of APOE e3/e4 and e4/e4 genotypes compared to DLB and HC (p <0.001).

  43. Multi-modal data analysis for early detection of alzheimer’s disease and related dementias

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. The Journal of Prevention of Alzheimer s Disease 2025-12-01 Getting a diagnosis

    Until recently, accurate early detection of clinical symptoms associated with Alzheimer's disease (AD) and related dementias (ADRD) has been difficult.

  44. Multimodal sensing and machine learning for continuous monitoring of agitation in dementia

    ✓ Peer-reviewed alzhub usefulness score 37 out of 100. Alzheimer s & Dementia 2025-12-01 Digital health tools

    So far, we included 42 patients in our study, that were monitored for at least 7 consecutive days and nights, to form the largest database of its kind in the world.

  45. Neuropathological evaluation of the Boston Criteria v2.0 for cerebral amyloid angiopathy in Alzheimer's disease dementia

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Alzheimer s & Dementia 2025-12-01 Treatments

    The Boston v2.0 criteria have low accuracy in patients with AD dementia.

  46. Neurophysiological markers of cholinergic dysfunction in pre‐symptomatic autosomal dominant Alzheimer´s disease using Transcranial Magnetic Stimulation (TMS): research design and preliminary results

    ✓ Peer-reviewed alzhub usefulness score 31 out of 100. Alzheimer s & Dementia 2025-12-01 Risk genes beyond APOE

    Here we present our research design and preliminary results in ADAD mutation carriers and controls.

  47. Quantitative EEG obtained from Dual‐Task paradigms for the study of preclinical populations at risk of Alzheimer Disease

    ✓ Peer-reviewed alzhub usefulness score 33 out of 100. Alzheimer s & Dementia 2025-12-01 Risk genes beyond APOE

    The most notable effect sizes were observed in entropy for Beta1 and Beta3 bands in frontal regions for the DTS7 and DTS1 tasks, Beta2 relative power in C4 during DTAN, Theta modulation in the Theta and alpha-1 bands in frontal regions during DTS7, and Alpha2 modulations in the same task.

  48. Quantitative EEG obtained from Dual‐Task paradigms for the study of preclinical populations at risk of Alzheimer Disease

    ✓ Peer-reviewed alzhub usefulness score 33 out of 100. Alzheimer s & Dementia 2025-12-01 Risk genes beyond APOE

    The most notable effect sizes were observed in entropy for Beta1 and Beta3 bands in frontal regions for the DTS7 and DTS1 tasks, Beta2 relative power in C4 during DTAN, Theta modulation in the Theta and alpha-1 bands in frontal regions during DTS7, and Alpha2 modulations in the same task.

  49. White Matter Hyperintensities Predict Driving Behavior Changes in Preclinical Alzheimer’s Disease

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. Alzheimer s & Dementia 2025-12-01 Risk factors

    Our study included 74,275 weeks of driving data (2015-2024, average follow-up 6.1 years).

  50. White Matter Hyperintensities Predict Driving Behavior Changes in Preclinical Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 50 out of 100. Alzheimer s & Dementia 2025-12-01 Risk factors

    Our study included 74,275 weeks of driving data (2015-2024, average follow-up 6.1 years).

From across this tag

8 of the 839 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 8. The same 8 appear here every time.

All topic tags with their study counts